Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CT-179 in Recurrent and Newly Diagnosed Glioblastoma
NCT07739017Phase 1Not yet recruiting
- Sponsor
- Olivia Newton-John Cancer Research Institute
- Start
- Dec 2026
- Primary completion
- Jun 2028
- Countries
- 1
01
Overview
Phase 1, open-label trial of CT-179 in glioblastoma (GBM) (2 arms), sponsored by Olivia Newton-John Cancer Research Institute. Primary endpoints: Maximum Tolerated Dose in Treatment Arm 1 at 28 days and Maximum Tolerated Dose / Recommended Phase 2 Dose in Treatment Arm 2 up to 12 weeks. Planned start Dec 2026; status: not yet recruiting.
02
Drugs
CT-179
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on NCT07739017.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07739017.